Atreca Inc
F:0C1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Atreca Inc
F:0C1
|
US |
|
R C M Technologies Inc
NASDAQ:RCMT
|
US |
|
S
|
Schweitzer-Mauduit International Inc
F:MH2
|
US |
|
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
US |
|
D
|
Datawalk SA
WSE:DAT
|
PL |
|
Weimob Inc
HKEX:2013
|
CN |
Atreca Inc
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
